Fierce Biotech: Labcorp’s Companion Diagnostic Cleared to Support Pfizer’s Gene Therapy for Hemophilia B

Labcorp has received FDA approval for a companion diagnostic to identify eligible patients for Pfizer’s Beqvez, the first gene therapy authorized in the U.S. for adults with moderately severe to severe hemophilia B. As reported by Fierce Biotech, the Labcorp-developed antibody screening test determines whether individuals carry preexisting neutralizing antibodies that could impact treatment success. This approval marks a significant advancement in the delivery of precision medicine for rare genetic disorders. Read the full article on Fierce Biotech to learn more about this important milestone.